1. Home
  2. NAMSW vs HCVI Comparison

NAMSW vs HCVI Comparison

Compare NAMSW & HCVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NAMSW
  • HCVI
  • Stock Information
  • Founded
  • NAMSW N/A
  • HCVI 2021
  • Country
  • NAMSW Netherlands
  • HCVI United States
  • Employees
  • NAMSW 29
  • HCVI N/A
  • Industry
  • NAMSW Biotechnology: Pharmaceutical Preparations
  • HCVI Blank Checks
  • Sector
  • NAMSW Health Care
  • HCVI Finance
  • Exchange
  • NAMSW Nasdaq
  • HCVI Nasdaq
  • Market Cap
  • NAMSW N/A
  • HCVI N/A
  • IPO Year
  • NAMSW N/A
  • HCVI 2021
  • Fundamental
  • Price
  • NAMSW $9.45
  • HCVI $10.57
  • Analyst Decision
  • NAMSW
  • HCVI
  • Analyst Count
  • NAMSW 0
  • HCVI 0
  • Target Price
  • NAMSW N/A
  • HCVI N/A
  • AVG Volume (30 Days)
  • NAMSW N/A
  • HCVI 19.4K
  • Earning Date
  • NAMSW N/A
  • HCVI 01-01-0001
  • Dividend Yield
  • NAMSW N/A
  • HCVI N/A
  • EPS Growth
  • NAMSW N/A
  • HCVI N/A
  • EPS
  • NAMSW N/A
  • HCVI N/A
  • Revenue
  • NAMSW N/A
  • HCVI N/A
  • Revenue This Year
  • NAMSW N/A
  • HCVI N/A
  • Revenue Next Year
  • NAMSW N/A
  • HCVI N/A
  • P/E Ratio
  • NAMSW N/A
  • HCVI N/A
  • Revenue Growth
  • NAMSW N/A
  • HCVI N/A
  • 52 Week Low
  • NAMSW N/A
  • HCVI $10.27
  • 52 Week High
  • NAMSW N/A
  • HCVI $11.47
  • Technical
  • Relative Strength Index (RSI)
  • NAMSW 50.58
  • HCVI 56.55
  • Support Level
  • NAMSW $9.40
  • HCVI $10.57
  • Resistance Level
  • NAMSW $10.14
  • HCVI $10.58
  • Average True Range (ATR)
  • NAMSW 0.48
  • HCVI 0.00
  • MACD
  • NAMSW 0.06
  • HCVI -0.00
  • Stochastic Oscillator
  • NAMSW 29.67
  • HCVI 66.67

About NAMSW NewAmsterdam Pharma Company N.V. Warrant

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.

About HCVI Hennessy Capital Investment Corp. VI

Hennessy Capital Investment Corp VI is a shell company.

Share on Social Networks: